WallStSmart
TOI

Oncology Institute Inc

NASDAQ: TOI · HEALTHCARE · MEDICAL CARE FACILITIES

$4.02
+2.74% today

Updated 2026-06-05

Market cap
$523.91M
P/E ratio
P/S ratio
0.96x
EPS (TTM)
$-0.35
Dividend yield
52W range
$2 – $6
Volume
1.6M

Oncology Institute Inc (TOI) Financial statements

SEC filings — annual and quarterly data.

Profit margin
-12.06%
Operating margin
-7.18%
ROE
-652.00%
ROA
-12.30%
Debt/equity
-1.61x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2018$113.16M$3.95M23.23%4.23%3.49%
2019$155.41M$-4.02M19.27%-1.70%-2.59%
2020$187.51M$-14.32M19.67%-4.37%-7.64%
2021$203.00M$-10.93M20.12%-22.59%-5.38%
2022$252.48M$152000.0020.63%-32.46%0.06%
2023$324.24M$-83.07M18.37%-23.75%-25.62%
2024$393.41M$-64.66M13.73%-15.28%-16.44%
2025$502.73M$-60.61M15.20%-7.18%-12.06%

Frequently asked questions

What is Oncology Institute Inc's revenue?

Oncology Institute Inc's trailing twelve-month revenue is $545.76M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is TOI?

In its most recent fiscal year, TOI ran a gross margin of 15.20%, an operating margin of -7.18%, and a net margin of -12.06%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does TOI generate?

TOI produced $-27.79M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is TOI's balance sheet healthy?

TOI holds $33.56M in cash and equivalents against $77.40M in long-term debt, on $-15.72M of shareholder equity. That debt is best read against the cash flow the business throws off each year.